类风湿关节炎中TNF抑制剂应答的预测因素:随机对照试验的个体患者数据汇总分析
该研究汇总29项随机对照试验的11617例类风湿关节炎患者个体数据,评估基线特征与TNF抑制剂应答的关系。至6个月时,肥胖患者EULAR无应答率显著更高(OR 0.52 vs 非肥胖者0.36,p=0.01)。多变量模型显示,病程每增加1年,最终DAS28(CRP)降低0.02(p<0.001);基线DAS28(CRP)>5.1者降低0.21(p<0.001)。
要点
- 肥胖类风湿关节炎患者使用TNF抑制剂至6个月时EULAR无应答率显著高于非肥胖者。
- 病程较长与TNF抑制剂治疗后DAS28(CRP)降幅更大相关。
- 基线高疾病活动度(DAS28(CRP)>5.1)与TNF抑制剂治疗后DAS28(CRP)降幅更大相关。
核心结论
- 在类风湿关节炎中,对TNF抑制剂应答更好的患者是非肥胖者、病程较长者和初始疾病活动度较高者。
研究设计与样本
- 汇总29项评估TNF抑制剂与安慰剂或常规治疗疗效的随机对照试验的个体患者数据。
- 按基线特征(吸烟状态、体力活动、性别、年龄、体重指数、自身抗体谱、病程、DAS28(CRP)>5.1定义的高初始疾病活动度)进行亚组分析。
- 主要终点为基线至6个月DAS28(CRP)变化在治疗组间的差异;次要终点为至6个月最终DAS28(CRP)及EULAR应答标准的组间差异。
- 各随机对照试验数据采用Mantel-Haenszel法以随机效应模型汇总,并在两个数据共享平台分别进行线性元回归以支持结果。
主要发现
- 共分析来自29项随机对照试验的11617例患者个体数据。
- 至6个月,肥胖患者EULAR无应答率显著高于非肥胖者(OR 0.52 vs 0.36,p=0.01)。
- 对7457例患者的多变量回归模型显示,接受TNF抑制剂治疗者病程每增加1年,最终DAS28(CRP)降低0.02(p<0.001)。
- 基线DAS28(CRP)>5.1者最终DAS28(CRP)降低0.21(p<0.001)。
关键数值与推荐
- 肥胖患者EULAR无应答OR 0.52 vs 非肥胖者0.36(p=0.01)。
- 病程每增加1年,最终DAS28(CRP)降低0.02(p<0.001)。
- 基线DAS28(CRP)>5.1者最终DAS28(CRP)降低0.21(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify patient characteristics associated with responsiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). MATERIALS AND METHODS: Individual patient data from 29 randomised controlled trials (RCTs) evaluating the efficacy of a TNFi versus placebo or conventional therapy were obtained. Response to treatment was assessed in subgroups according to the following baseline characteristics: smoking status, physical activity, sex, age, body mass index, autoantibody profile, disease duration, high initial disease activity defined by Disease Activity Score on 28 joints (DAS28)(C reactive protein (CRP)) >5.1. The primary outcome was the between-treatment group difference in DAS28(CRP) change from baseline to 6 months. The secondary endpoints were the between-treatment group difference in final DAS28(CRP) measured until 6 months and EULAR response criteria until 6 months. Data from each RCT were then pooled by the Mantel-Haenszel method using a random effects model. A linear metaregression was also carried out on two data-sharing platforms separately to support the results. RESULTS: Individual data of 11 617 patients from 29 RCTs were analysed. Until 6 months, a significantly higher EULAR non-response rate was observed in obese patients (OR 0.52 vs 0.36 for non-obese, p=0.01). A multivariable regression model performed on 7457 patients indicated that patients treated by TNFi had a final DAS28(CRP) decreased by 0.02 for each year of disease duration (p<0.001), and a 0.21 decreased for patients with a baseline DAS28(CRP) >5.1 (p<0.001). CONCLUSIONS: In RA, patients who are more responsive to TNFi are those who are non-obese, have a long disease duration and have a high initial disease activity.
引用
- Law-Wan J, Sparfel MA, Derolez S, et al. Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. RMD Open. 2021. PMID: 34789535. doi:10.1136/rmdopen-2021-001882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。